Regorafenib plus envafolimab versus physician's choice for metastatic GIST with KIT exon 17 mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective phase II randomized trial enrolling about 100 patients with metastatic GIST harboring KIT exon 17 mutations who progressed after standard therapies. Participants are randomized 1:1 to receive regorafenib plus envafolimab (regorafenib 120 mg orally daily, 3 weeks on/1 week off; envafolimab 200 mg subcutaneously every 2 weeks) or physician-selected targeted therapy or combinations. Treatment continues until disease progression, unacceptable toxicity, or withdrawal, with imaging assessments at baseline and every two months. The study will measure efficacy and safety and explore how features of the tumor immune microenvironment relate to response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥ 18 years, regardless of gender;
* Confirmed as gastrointestinal stromal tumor by histopathological examination;
* Having at least one measurable target lesion meeting the criteria of mRECIST v1.1 (non-lymph node lesions with a long axis ≥ 1.0 cm or a long axis ≥ the thickness of 2 slides); imaging assessment should be performed within 14 days before the first medication;
* Disease progression or intolerance after treatment with imatinib, sunitinib, regorafenib, or ripretinib;
* Primary or secondary KIT exon 17 mutation detected by genetic testing;
* Sufficient organ and bone marrow function, defined as follows: Blood routine: Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L; platelet count (PLT) ≥ 75×10⁹/L; hemoglobin (HGB) ≥ 9.0 g/dL. No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), red blood cell transfusion, or platelet transfusion within 14 days before the examination; Liver and kidney function: For subjects without liver metastasis, serum total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN. For subjects with liver metastasis: TBIL ≤ 1.5×ULN; ALT and AST ≤ 5×ULN. Renal function: Serum creatinine (Scr) ≤ 1.5×ULN; Sufficient coagulation function, defined as international normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5×ULN; if the subject is receiving anticoagulant therapy, it is acceptable as long as PT is within the range specified for the anticoagulant drug;
* Provide 15 paraffin-embedded tissue sections before enrollment for immune microenvironment detection;
* ECOG PS score of 0-2;
* Signed informed consent form.

Exclusion Criteria:

* A history of intolerance to regorafenib treatment, or previous receipt of immune checkpoint inhibitor therapy;
* Being in pregnancy or lactation;
* Those with an expected survival period of less than 3 months;
* Those who have undergone major surgery or suffered significant trauma within 4 weeks before the first blood collection during the screening period, or are expected to require major surgery during the study period;
* Patients with current active ulcers or gastrointestinal bleeding;
* A history of interstitial lung disease or non-infectious pneumonia; a history of active tuberculosis;
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
* Patients with clinically confirmed autoimmune diseases; those with positive HIV or HCV; those with HBV-DNA exceeding the laboratory normal range; those with acute CMV infection;
* Patients with clinically confirmed central nervous system metastases;
* Patients with other malignant tumors within 5 years;
* Immunosuppressed subjects, including those with known immunodeficiency; those currently receiving systemic steroid medications (except those who have used inhaled steroids recently or currently);
* Uncontrolled hypertension: After active antihypertensive treatment, three consecutive blood pressure measurements indicate systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg;
* Subjects who, in the investigator's assessment, are unable or unwilling to comply with the requirements of the study protocol.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jian Li, MD
• Email: oncogene@163.com
• Phone: +86 010 88196561

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GIST Patient Registry for real-world insights

  This registry collects medical information from people with GIST to see how the disease behaves in real life and to help improve care.

  Recruiting The Life Raft Group · Wayne, New Jersey · NCT07697248

• First-line chemo with hepatic arterial infusion plus Envafolimab and Lenvatinib for unresectable biliary tract cancer

  This trial tests a first-line treatment combining hepatic arterial infusion chemotherapy with Envafolimab and Lenvatinib to see if it helps patients with unresectable biliary tract cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07636798

• Two-tooth endoscopic clip to help remove and close stomach GISTs

  Doctors will try a new two-tooth endoscopic clip used with a clip-and-line traction method during ESD and EFTR to see if it makes removing and closing gastric GISTs (2–5 cm) faster and safer for adults.

  Recruiting Affiliated Hospital to Academy of Military Medical Sciences · Beijing · NCT07581977

• Envafolimab in real-world use for advanced solid tumors

  This study looks at real-world safety and effectiveness of Envafolimab given as a patient-access program for adults with advanced solid tumors.

  Recruiting Ir Innovate Research Private Limited · Nairobi and 3 other locations · NCT07562347

• KQB198 plus imatinib for first-line advanced or metastatic GIST

  This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.

  Recruiting at 17 sites Phase 2 Kumquat Biosciences Inc. · Los Angeles, California and 16 other locations · NCT07406633

• NB003 for Advanced GIST: testing a new therapy vs regorafenib in adults

  This trial tests NB003 in adults with advanced GI stromal tumors who have progressed on or cannot tolerate imatinib and sunitinib, comparing NB003 to regorafenib in different lines of therapy.

  Recruiting at 4 sites Phase 2/3 Ningbo Newbay Technology Development Co., Ltd · Hefei, Anhui and 31 other locations · NCT07379047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.